anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Previous studies have indicated that a higher ventilatory ratio (VR) is associated with mortality. However, it is unknown whether dynamic changes in VR over time affect the prognosis of critically ill patients. This study aims to investigate the significance of VR during the progression of the disease in critically ill patients. The Medical Information Mart for Intensive Care III database was searched to identify critically ill patients. The primary outcome was 30-day mortality. Multivariable Cox regression was used to elucidate the relationship between the VR and mortality. Finally, we employed a generalized additive mixed model to compare trends in VR over time between survivors and non-survivors. A total of 8024 patients were enrolled. Multivariable Cox regression analysis identified a baseline VR ≥1.89 as an independent risk factor predicting 30-day mortality (hazard ratio: 2.10, 95% confidence interval: 1.89-2.33, P < .001) and 90-day mortality (hazard ratio: 2.18, 95% confidence interval: 1.97-2.41, P < .001) after adjusting for potential confounders. In the subgroup analyses, the observed association between VR and 30-day mortality showed consistent direction across most subgroups. The generalized additive mixed model results highlighted that the difference in VR between survivors and non-survivors increased by an average of 0.01 per day after adjusting for several covariates. In conclusion, VR dynamically mirrors pathophysiological changes in critically ill patients and its escalation is linked to higher mortality rates. Monitoring VR's dynamic shifts might offer more immediate prognostic information, thus aiding in timely interventions and risk stratification.
All registered participants in the intervention group, will receive the intramuscular injection with Routine Technique. Routine Technique involved inserting the injection intra muscularly at 90 degree angle into Dorso gluteal muscles without tapping after cleaning with alcohol swab.
A healthcare provider may access a healthcare provider portal to a health records management system. The health records management system may identify which vaccinations are covered by the employer's insurance. The healthcare provider may select vaccinations which the healthcare provide has in inventory. Employees may access a patient portal. The health records management system may verify for which vaccinations the patient is due. The employees select their desired vaccines. The health records management system may create appointments for the employees, and the healthcare provider may view the appointments and provide the desired vaccines to the employees.
Systems, devices, and methods are disclosed for wireless communication of analyte data. One such method includes, during a first interval, establishing a first connection between an analyte sensor system and a display device. During the first connection, the method includes exchanging information related to authentication between the analyte sensor system and the display device. The method includes making a determination regarding whether authentication was performed during the first interval. During a second interval, the method may include establishing a second connection between the analyte sensor system and the display device for transmission of an encrypted analyte value, and bypassing the exchanging of information related to authentication performed during the first connection. The method also includes, during the second interval, the analyte sensor system transmitting the encrypted analyte value to the display device, if the determination indicates that the authentication was performed during the first interval.
Receives 4 weeks of mindfulness training followed by a testing session. Then, 4 weeks of no-training interval followed by a testing session.
PURPOSE:To obtain a bathing agent having improved dispersibility and solubility in hot water by improving physical properties of SAKE (Japanese rice wine) lees and to provide a process for the production of the agent. CONSTITUTION:A liquid bathing agent containing SAKE lees treated with an enzyme and a powdery bathing agent produced by pulverizing the liquid bathing agent. The liquid bathing agent can be produced by adding water to SAKE lees, stirring the mixture to form a homogeneous dispersion, crushing in wet state to finely pulverize the SAKE lees to obtain SAKE lees colloid and subjecting the colloidal SAKE lees to enzymatic treatment. The powdery bathing agent is obtained by drying and pulverizing the liquid bathing agent. The enzyme is preferably protease, cellulase, glucanase, etc., or their mixture. A bathing agent easily dispersible or soluble in hot water is produced by the enzymatic treatment of SAKE leer. The smoothness to the skin is improved by the decomposition of crude fiber and the humectant effect and skin- beautifying effect can be improved by the increase in amino acid and lipid.
BACKGROUND: TRY-NAD metabolic network includes TRY (tryptophan), 5-HT (5-hydroxytryptamine), KYN (kynurenine), and NAD (nicotinamide adenine dinucleotide) pathway, which plays a significant role in neurological diseases and ageing. It is important to monitor these metabolites for studying the pathological anatomy of disease and treatment of responses evaluation. Although previous studies have reported quantitative methods for several metabolites in the network, the bottlenecks of simultaneously quantifying the whole metabolic network are their similar structures, diverse physico-chemical properties, and instability. Standardized protocols for the whole metabolic network are still missing, which hinders the in-depth study of TRY-NAD metabolic network in laboratory research and clinical screening.
RESULTS: We developed a LC-MS/MS method for quantifying 28 metabolites in the TRY-NAD network simultaneously. Optimization was done for the mass spectral parameters, chromatographic conditions and sample pretreatment process. The developed method was fully validated in terms of standard curves, sensitivity, carryover, recovery, matrix effect, accuracy, precision, and stability. The pretreatment of 30 samples only takes 90 min, and the LC-MS/MS running time of one sample is only 13 min. With this method, we bring to light the chaos of global TRY-NAD metabolic network in sleep deprivation mice for the first time, including serum, clotted blood cells, hippocampus, cerebral cortex, and liver. NAD pathway levels in brain and blood decreased, whereas the opposite happened in the liver. The 5-HT pathway decreased and the concentration of KYN increased significantly in the brain. The concentration of many metabolites in KYN pathway (NAD+ de novo synthesis pathway) increased in the liver.
SIGNIFICANCE: This method is the first time to determine the metabolites of KYN, 5-HT and NAD pathway at the same time, and it is found that TRY-NAD metabolic network will be disordered after sleep deprivation. This work clarifies the importance of the pH of the extraction solution, the time and temperature control in pretreatment in standardized protocols building, and overcoming the problems of inconsistent sample pretreatment, separation, matrix effect interference and potential metabolite degradation. This method exhibits great prospects in providing more information on metabolic disturbances caused by sleep deprivation as well as neurological diseases and ageing.
A suspension of fibrinogen, thrombin, alcohol and optionally aprotinin is obtained by mixing fibrinogen in alcohol with thrombin in alcohol. The suspension contains fibrinogen and thrombin particles with a Folk Ward mean diameter of 25 - 100 m. The thrombin may be human, bovine or recombinant. The fibrinogen may be human or recombinant. A method for coating a carrier, such as a collagen sponge, with the suspension, and a method for drying the coating is disclosed. The coated collagen carrier may be used as a ready-to-use absorbable composition for tissue gluing, tissue sealing and haemostasis wherein the carrier is coated with solidly fixed components of fibrin glue, i.e. fibrinogen and thrombin.
Anesthesia was induced with propofol (2.0-3.5 μg/mL) by target control infusion and 0.3-0.5 μg/kg sufentanil. Tracheal intubation was facilitated by rocuronium (1.0 mg/kg). Anesthesia was maintained using isoflurane at 0.7-1.0 minimal alveolar concentration in a gas mixture of oxygen and air and remifentanil (0.05-0.2 μg·kg-1·min-1) by intravenous injection pump. Sufentanil dose was totally 2.5-4.0 μg/kg. Muscle relaxation was achieved using 1/3-1/4 of the induction dose every 40-60 min based on a train of four. Mechanical ventilation with 80% O2 in air was used. Tidal volume (7-8 mL/kg) and respiratory rate (10-12/min) were adjusted according to PETCO2 to achieve normal ventilation (PETCO2 35-45 mmHg).
The design is primarily a randomized control-trial design (2 sessions), testing the effects of single-pulse TMS on reward processing during goal-directed behavior tasks. Subjects will be randomly assigned to an peak or trough group. All participants will be asked to complete two TMS sessions within two weeks. For each TMS session, participants will receive either Active TMS or Sham TMS. For each TMS session, the TMS coil will be placed 1cm above the scalp over a left frontal region (electrode location F3). Subjects will be randomly assigned to an active or sham condition for each session. At the start of the first TMS session, participants will be fitted with an EEG cap and engage in a virtual T-maze reward task. The T-maze task will be divided into 30 blocks of trials. For the first block of 10 trials, a single TMS pulse will be delivered over the DLPFC immediately following trial-to-trial feedback and at the desired theta phase. Reward stimulus (apple or orange) will indicate whether the participant will receive 5 or 0 cents on that trial. Immediately following this block, subjects will complete 5 trials with no modulation. This block sequence will repeat for 30 blocks for a total of 300 pulses delivered and 450 T-maze trials completed (duration 15 minutes: 300 TMS trials, 150 no-TMS trials). TMS pulse delivery will be open for 1 second and only 1 pulse will be delivered within this time range. Following the T-maze, participants will engage in the probabilistic selection task. During the learning phase of the PST, subjects will again receive a single TMS pulse at the desired theta phase following feedback onset. A total of 240 pulses will be delivered and 240 learning phase trials will be completed before subjects perform the test phase (duration 15-20 minutes). Identical protocol will be applied to the second Sham session (1-week later). Participants will be debriefed and compensated for their participation.
Fifty-three percent (531/1,008) of patients receiving EFV, a component of efavirenz, lamivudine and tenofovir disoproxil fumarate tablets, in controlled trials reported central nervous system symptoms (any grade, regardless of causality) compared to 25% (156/635) of patients receiving control regimens. These symptoms included, but were not limited to, dizziness (28.1% of the 1,008 patients), insomnia (16.3%), impaired concentration (8.3%), somnolence (7.0%), abnormal dreams (6.2%), and hallucinations (1.2%). These symptoms were severe in 2.0% of patients and 2.1% of patients discontinued therapy as a result. These symptoms usually begin during the first or second day of therapy and generally resolve after the first 2 to 4 weeks of therapy. After 4 weeks of therapy, the prevalence of nervous system symptoms of at least moderate severity ranged from 5% to 9% in patients treated with regimens containing EFV and from 3% to 5% in patients treated with a control regimen. Inform patients that these common symptoms were likely to improve with continued therapy and were not predictive of subsequent onset of the less frequent psychiatric symptoms [see Warnings and Precautions (5.5)]. Dosing at bedtime may improve the tolerability of these nervous system symptoms [see Dosage and Administration (2.2)].

  
  


Late-onset neurotoxicity, including ataxia and encephalopathy (impaired consciousness, confusion, psychomotor slowing, psychosis, delirium), may occur months to years after beginning efavirenz therapy. Some events of late-onset neurotoxicity have occurred in patients with CYP2B6 genetic polymorphisms which are associated with increased efavirenz levels despite daily dosages of 600 mg of efavirenz. Patients presenting with signs and symptoms of serious neurologic adverse experiences should be evaluated promptly to assess the possibility that these events may be related to efavirenz use, and whether discontinuation of efavirenz, lamivudine and tenofovir disoproxil fumarate tablets is warranted.
This invention discloses a method, system, and computer-readable storage medium for detecting EGFR gene mutations. The method involves receiving chest CT images, extracting feature variables of multiple target radiomic features from these images. Each target radiomic feature exhibits no significant difference between chest plain CT and enhanced CT at the first significance level but demonstrates significant differences between EGFR mutation-positive and EGFR mutation-negative at the second significance level. By utilizing a regression model and these feature variables, scoring values corresponding to the chest CT images under processing are obtained. Based on these scoring values, the detection result of EGFR gene mutations in lung cancer patients corresponding to the chest CT images under processing is determined. These results reflect the probability of EGFR gene mutations. This method can detect EGFR gene mutations based on chest plain CT or enhanced CT images and has a broad scope of clinical applications.
AIM: Validated assessment tools are needed to identify clinically high risk for psychosis. This study aimed to validate the early recognition inventory ERIraos, which consists of the ERIraos Checklist for risk screening and the ERIraos Symptom List for a more thorough risk assessment in the Estonian language to detect psychotic prodromal symptoms.
METHODS: A prospective cohort study provided an opportunity to evaluate the characteristics of the ERIraos instrument in predicting the increased risk of a psychotic disorder in the future. The 177 study participants, aged 13-42 years old, were divided into groups without an increased risk and three risk groups with different risk severity levels based on the ERIraos Symptom List assessment.
RESULTS: The results indicated excellent inter-rater reliability for the ERIraos Symptom List total score. The ability of the ERIraos checklist to screen persons with an elevated psychosis risk was very good (ROC-AUC = 0.86). The capability of the ERIraos Symptom List scores to predict the probability of transitioning to psychosis within 2 years was very good (ROC-AUC = 0.83). Brief limited intermittent psychotic symptoms and observable behavioural and affective symptoms were statistically significant predictors of transition to psychosis. There were strong and statistically significant correlations between the ERIraos Symptom List scores and other clinical measures assessing functioning and psychopathology.
CONCLUSIONS: The results of this study demonstrate the reliability and validity of the Estonian version of the ERIraos instrument and support the usability of ERIraos as a two-step tool for the early recognition of psychosis risk.
Obesity is one of the greatest threats to modern public health. It is associated with negative physical and mental health outcomes as well as increased healthcare expenditures. Throughout the time period that the prevalence of overweight and obesity have been monitored in the United States, men have consistently been more likely than women to be overweight and; conversely, women have been more likely to be obese. Recent trends suggest that this situation may be changing. Over the past decade, the prevalence of obesity has increased among men while it has stabilized among women. For the first time, men and women have near equal rates of obesity where approximately 35.7% of American adults are classified as obese; meanwhile, men continue to be more overweight than women.

The epidemiological trends have lead to a focus on creating weight loss programs that can aid overweight and obese adults in losing excess weight. Behavioral interventions for obesity have demonstrated the ability to produce weight losses of approximately 5-10% of initial body weight. These weight losses have been associated with decreased risk for type II diabetes, reduced blood pressure, and improvement in mental health outcomes. Unfortunately, men typically do not take advantage of such programs. Across multiple literature reviews, men consistently make up approximately 27% of study samples. This has lead to a situation where researchers have little information about how to enroll men in weight loss programs and what kind of programs are of interest to men. In order to combat the increased obesity in men and help them to avoid the negative consequences of obesity, it is important to help overweight and obese men change their eating and physical activity habits within the context of organized weight loss programs.

The REFIT (Rethinking Eating and FITness) intervention is an intervention developed to address men's needs for weight loss while balancing their need to perform behaviors which are seen as masculine. Men typically eat a diet that is associated with weight gain rather than weight loss. The REFIT intervention will focus on changing eating and exercise behaviors within a structured weight loss program that will allow men to maintain their autonomy. Autonomy is a central characteristic of enacted masculinity and has been described in qualitative research as a necessary aspect of a weight loss program for men. The intervention will focus on encouraging changes in eating and activity through increasing self-efficacy, autonomous motivation, outcome expectancies, and self-regulation for weight loss behaviors. The development of this intervention has been guided by qualitative research focused on what men want and need from weight loss programs as well as previous research focused on weight loss among both men and women. The approach to be used in the REFIT intervention is innovative as a combination of the "small changes" approach that has been used in weight gain prevention as well as the client centered deficit approaches used by Lutes and colleagues and Sbrocco and colleagues in weight loss programs.
Certain examples of the present disclosure relate to systems and methods for controlling a vehicle. In particular, the present disclosure provides systems and methods for moving an aerial vehicle by decoupling the pitch- and roll-movement from thrust production. This decoupling can occur by shifting the center of gravity of the vehicle to create a moment about a desired axis. Some examples describe single-shaft rotary vehicles, while other examples describe coaxial rotary vehicles. The vehicles described herein may include a first mass moveable from a first position to a second position to create at least one of a rolling moment or a pitching moment to alter the direction of movement of the vehicle. A second mass may also be provided to alter the rolling moment or pitching moment. Methods for controlling the vehicles are also provided herein.
The present invention discloses a compound cordyceps liquid capsule. Its contents are formed from 22 weight portions of compound cordyceps extract powder, 36.6 weight portions of soya bean oil and 1.4 weight portions of beeswax. The described compound cordyceps extract powder is made up by using 6 Chinese medicinal materials of cordyceps, epimedium, lyceum berry, crataegus fruit, nardostachys root and royal jelly through the processes of extraction and drying. The preparing method of the compound cordyceps liquid capsule comprises the following steps: heating the soya bean oil and the beeswax to 60 DGE C-70 DGE C, stirring and dissolving, and keeping the temperature at 60 DGE C-70 DGE C; putting the compound cordyceps extract powder into the solution to blend, then sifting through 100 order, putting into the apparatus for filling liquid capsule to form the said capsule. The compound cordyceps liquid capsule prepared and inspected according to the invention belongs to hard capsule, but the content contained therein is liquid, therefore many steps before filling capsule can be saved and the investment of the needed devices can be reduced. Comparing with oral administration liquid, the capsule of the invention has the advantages that it is convenient to store, carry and orally take, moreover, its quality is more stable. Due to the liquid capsule does not contain the sugar, it is suitable for much more people.
Tramadol hydrochloride extended-release tablet is a mu-agonist opioid. Tramadol, like other opioids used in analgesia, can be abused and is subject to criminal diversion.

Drug addiction is characterized by compulsive use, use for non-medical purposes, and continued use despite harm or risk of harm. Drug addiction is a treatable disease, utilizing a multi-disciplinary approach, but relapse is common.

“Drug-seeking” behavior is very common in addicts and drug abusers. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing or referral, repeated “loss” of prescriptions, tampering with prescriptions and reluctance to provide prior medical records or contact information for other treating physician(s). “Doctor shopping” to obtain additional prescriptions is common among drug abusers and people suffering from untreated addiction.

Abuse and addiction are separate and distinct from physical dependence and tolerance. Physicians should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical dependence in all addicts. In addition, abuse of opioids can occur in the absence of true addiction and is characterized by misuse for non- medical purposes, often in combination with other psychoactive substances. Tramadol hydrochloride extended-release tablets, like other opioids, may be diverted for non-medical use. Careful record-keeping of prescribing information, including quantity, frequency, and renewal requests is strongly advised.

Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs. 

Tramadol hydrochloride extended-release tablets are intended for oral use only. The crushed tablet poses a hazard of overdose and death. This risk is increased with concurrent abuse of alcohol and other substances. With parenteral abuse, the tablet excipients can be expected to result in local tissue necrosis, infection, pulmonary granulomas, and increased risk of endocarditis and valvular heart injury. Parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and HIV.